Scinai leadership to attend BIO-Europe Spring 2024
- None.
- None.
Showcasing Company's cGMP biologics CDMO and innovative NanoAb pipeline
Several members of Scinai's leadership team will be available for discussions with:
- Prospective clients of the company's end-to-end biologics CDMO services.
- Potential pharma partners in the field of dermatology interested in co-advancing or in-licensing Scinai's innovative NanoAb for local treatment of mild to moderate plaque psoriasis – "the Botox-like solution for psoriatic patients".
- Institutional and private investors interested in SCNI's value proposition.
All interested parties are encouraged to schedule a meeting through the conference partnering platform or to email Scinai at bd@scinai.com to schedule a meeting. Throughout the conference, Scinai will also be available at exhibitor booth #119 to showcase its CDMO services.
Scinai's CEO, Amir Reichman, provided an overview of Scinai's assets and plans in this brief introductory video: https://www.youtube.com/watch?v=eWz0E_-ogSc.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
CDMO and Partnering | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, the potential of Scinai's NanoAb pipeline, and the expansion of the CDMO business and the timing of human clinical trials. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to, the risk of delay in, or Scinai's inability to conduct, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not remain listed on Nasdaq; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; the risk that the European Investment Bank (EIB) may accelerate the financial facility under its finance contract with Scinai; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in
Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/scinai-leadership-to-attend-bio-europe-spring-2024-302086651.html
SOURCE Scinai Immunotherapeutics Ltd.
FAQ
What will Scinai Immunotherapeutics Ltd. be showcasing at the BIO-Europe Spring 2024 conference?
What are the key objectives of Scinai at the conference?
How can interested parties schedule a meeting with Scinai at the conference?
Who will be available for discussions at Scinai's booth #119?
